Table 5 Statistical analysis of patient characteristics of RFS data

Age

0.007

1.011 [1.003–1.019]

0.006

1.012 [1.004–1.021]

Gender (female vs. male)

 < 0.001

0.632 [0.550–0.726]

0.038

0.806 [0.657–0.988]

Smoking history (+ vs. –)

 < 0.001

1.519 [1.319–1.748]

0.552

0.938 [0.761–1.157]

Operation time

 < 0.001

1.003 [1.002–1.004]

 < 0.001

1.002 [1.001–1.003]

Invasion

Lymphatic vessel invasion (+ vs. –)

 < 0.001

3.123 [2.706–3.605]

0.002

1.330 [1.113–1.590]

Vascular invasion (+ vs. –)

 < 0.001

3.206 [2.779–3.698]

 < 0.001

1.377 [1.155–1.643]

Pleural invasion (+ vs. –)

 < 0.001

2.574 [2.243–2.954]

0.448

1.070 [0.899–1.274]

Adenocarcinoma predominance

AIS + MIA

control

control

Lepidic

0.01

1.694 [1.132 – 2.533]

0.678

1.100 [0.702 – 1.722]

Acinar + Papillary + Variants

 < 0.001

3.952 [2.783–5.611]

0.012

1.686 [1.124 – 2.530]

Solid + Micropapillary

 < 0.001

7.041 [4.820–10.285]

 < 0.001

2.221 [1.421—3.472]

EGFR status (+ vs. –)

0.205

0.902 [0.768–1.058]

Adjuvant chemotherapy (+ vs. –)

 < 0.001

0.481[0.420—0.537]

0.016

0.812 [0.686—0.962]

Clinical stage

Stage IA

control

control

Stage IB

 < 0.001

1.802 [1.535—2.115]

0.332

1.099 [0.908—1.329]

Stage IIA

 < 0.001

3.097 [2.481—3.866]

0.19

1.191 [0.917—1.546]

Stage IIB

 < 0.001

3.916 [2.913—5.266]

0.024

1.500 [1.055—2.135]

Stage IIIA

 < 0.001

5.774 [4.505—7.401]

0.017

1.454 [1.069—1.978]

Pathological stage

Stage IA

control

control

Stage IB

 < 0.001

2.556 [2.097—3.116]

 < 0.001

1.888 [1.459—2.442]

Stage IIA

 < 0.001

5.767 [4.621—7.197]

 < 0.001

3.482 [2.613—4.640]

Stage IIB

 < 0.001

7.042 [5.316—9.328]

 < 0.001

3.953 [2.737—5.710]

Stage IIIA

 < 0.001

10.288 [8.462—12.508

 < 0.001

5.681 [4.247—7.600]